ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA(R) Plus CAR-NK, Chemo-Free Therapy

At study entry, patients demonstrated immune compromise consistent with prior standard of care, including radiation and alkylating chemotherapy. The baseline mean absolute lymphocyte count (ALC) was ...
The American Journal of Managed Care

Studies Highlight Prognostic Value of Neutrophil-to-Lymphocyte Ratio in MPNs

Neutrophil-to-lymphocyte ratio (NLR) is a significant prognostic indicator in myeloproliferative neoplasms, correlating with mortality and thrombotic risk. In polycythemia vera, an NLR of at least 5 ...
Arizona Daily Star

To your good health: Low lymphocyte count is cause for concern

DEAR DR. ROACH: I am a 58-year-old male. Several months ago, I lost 17 pounds, and even though I have gained back about 2 pounds in the past month, I cannot gain the weight back, even by increasing my ...

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lun…

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
Medscape

Myeloma: Can Lymphopenia Help Predict Patient Outcomes?

The analysis of 11,427 Veterans Administration (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 ...
Business Wire

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value ...